Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics

Biochemical and Biophysical Research Communications

Volumn 446, Issue 4, 2014, Pages 863-869

  Sahasrabuddhe, Nandini A ^a   Barbhuiya, Mustafa A ^b   Bhunia, Shushruta ^b   Subbannayya, Tejaswini ^a,d   Gowda, Harsha ^a   Advani, Jayshree ^a   Shrivastav, Braj R ^e   Navani, Sanjay ^f   Leal, Pamela ^c,g   Roa, Juan Carlos ^h   Chaerkady, Raghothama ^c   Gupta, Sanjeev ^e   Chatterjee, Aditi ^a   Pandey, Akhilesh ^a,c   Tiwari, Pramod K ^b  

^a INSTITUTE OF BIOINFORMATICS   (India)

^b JIWAJI UNIVERSITY   (India)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMRITA UNIVERSITY   (India)

^e Cancer Hospital and Research Institute   (India)

^f Lab Surgpath   (India)

^g UNIVERSIDAD DE LA FRONTERA   (Chile)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Biomarkers; Gallbladder cancer; iTRAQ; Prosaposin; Quantitative proteomics; Transgelin

Indexed keywords

BIOMARKERS; GALLBLADDER CANCER; ITRAQ; PROSAPOSIN; QUANTITATIVE PROTEOMICS; TRANSGELIN;

CHROMATOGRAPHY, LIQUID; GALLBLADDER; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; PROTEOME; PROTEOMICS; SAPOSINS; TANDEM MASS SPECTROMETRY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899471783     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.017     Document Type: Article

References (43)

1. E.C. Lazcano-Ponce, J.F. Miquel, N. Munoz, and R. Herrero et al. Epidemiology and molecular pathology of gallbladder cancer CA Cancer J. Clin. 51 2001 349 364
2. G. Randi, S. Franceschi, and C. La Vecchia Gallbladder cancer worldwide: geographical distribution and risk factors Int. J. Cancer 118 2006 1591 1602
3. S. Misra, A. Chaturvedi, N. Misra, and I. Sharma Carcinoma of the gallbladder Lancet Oncol. 4 2003 167 176
4. R. Goldin, and J. Roa Gallbladder cancer: a morphological and molecular update Histopathology 55 2009 218 229
5. Y. Kim, J. Kim, Y. Jang, and W. Lee et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma Cancer Lett. 169 2001 59 68
6. H. Alvarez, A. Corvalan, J.C. Roa, and P. Argani et al. Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer Clin. Cancer Res. 14 2008 2631 2638
7. J.H. Kim, H.N. Kim, K.T. Lee, and J.K. Lee et al. Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis Tumour Biol. 29 2008 41 49
8. J.W. Wang, S.Y. Peng, J.T. Li, and Y. Wang et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1 Cancer Lett. 281 2009 71 81
9. Y. Tan, S.Y. Ma, F.Q. Wang, and H.P. Meng et al. Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer Oncol. Rep. 26 2011 853 859
10. B.L. Strom, G. Maislin, S.L. West, and B. Atkinson et al. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int. J. Cancer 45 1990 821 824
11. A. Chaube, M. Tewari, U. Singh, and H.S. Shukla CA 125: a potential tumor marker for gallbladder cancer J. Surg. Oncol. 93 2006 665 669
12. H. Pawar, M.K. Kashyap, N.A. Sahasrabuddhe, and S. Renuse et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery Cancer Biol ther. 12 2011 510 522
13. J. Rappsilber, M. Mann, and Y. Ishihama Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips Nat. Protoc. 2 2007 1896 1906
14. K. Kandasamy, A. Pandey, and H. Molina Evaluation of several MS/MS search algorithms for analysis of spectra derived from electron transfer dissociation experiments Anal. Chem. 81 2009 7170 7180
15. J.A. Vizcaino, R.G. Cote, A. Csordas, and J.A. Dianes et al the PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013 Nucleic Acids Res. 41 2013 D1063 D1069
16. R. Goel, B. Muthusamy, A. Pandey, and T.S. Prasad Human protein reference database and human proteinpedia as discovery resources for molecular biotechnology Mol. Biotechnol. 48 2011 87 95
17. N. Dursun, O.T. Escalona, J.C. Roa, and O. Basturk et al. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas Arch. Pathol. Lab. Med. 136 2012 1347 1358
18. S.Y. Park, S.J. Roh, Y.N. Kim, and S.Z. Kim et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact Oncol. Rep. 22 2009 649 657
19. A. Kikuchi, T. Ishikawa, K. Mogushi, and M. Ishiguro et al. Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis Int. J. Cancer 132 2013 2295 2302
20. P. Ziolkowski, E. Gamian, B. Osiecka, and A. Zougman et al. Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast J. Biomed. Biotechnol. 2009 2009 919645
21. S.R. Hustinx, D. Cao, A. Maitra, and N. Sato et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression Cancer Biol ther. 3 2004 1254 1261
22. W. Cheung, M.M. Darfler, H. Alvarez, and B.L. Hood et al. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors Pancreatology 8 2008 608 616
23. S.C. Chauhan, M.C. Ebeling, D.M. Maher, and M.D. Koch et al. MUC13 mucin augments pancreatic tumorigenesis Mol. Cancer Ther. 11 2012 24 33
24. B.K. Gupta, D.M. Maher, M.C. Ebeling, and V. Sundram et al. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer J. Histochem. Cytochem. 60 2012 822 831
25. H.J. Lee, K.T. Nam, H.S. Park, and M.A. Kim et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer Gastroenterology 139 213-225 2010 e213
26. T. Shimamura, H. Ito, J. Shibahara, and A. Watanabe et al. Overexpression of MUC13 is associated with intestinal-type gastric cancer Cancer Sci. 96 2005 265 273
27. S. Koochekpour, S. Hu, C. Vellasco-Gonzalez, and R. Bernardo et al. Serum prosaposin levels are increased in patients with advanced prostate cancer Prostate 72 2012 253 269
28. Y. Wu, L. Sun, W. Zou, and J. Xu et al. Prosaposin, a regulator of estrogen receptor alpha, promotes breast cancer growth Cancer Sci. 103 2012 1820 1825
29. J. Wang, L. Chen, Y. Li, and X.Y. Guan Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma PLoS One 6 2011 e24967
30. Z. Jevnikar, M. Rojnik, P. Jamnik, and B. Doljak et al. Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells J. Biol. Chem. 288 2013 2201 2209
31. M.S. Kim, X. Chang, C. LeBron, and J.K. Nagpal et al. Neurofilament heavy polypeptide regulates the Akt-beta-catenin pathway in human esophageal squamous cell carcinoma PLoS One 5 2010 e9003
32. F. Zhu, L. Jin, T.P. Luo, and G.H. Luo et al. Serine protease HtrA1 expression in human hepatocellular carcinoma Hepatobiliary Pancreat. Dis. Int. 9 2010 508 512
33. P.D. Prasad, J.A. Stanton, and S.J. Assinder Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer Cell Tissue Res. 339 2010 337 347
34. B. Ogretmen, and Y.A. Hannun Biologically active sphingolipids in cancer pathogenesis and treatment Nat. Rev. Cancer 4 2004 604 616
35. J.M. Shields, K. Rogers-Graham, and C.J. Der Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways J. Biol. Chem. 277 2002 9790 9799
36. R. Nair, J. Solway, and D. Boyd Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression J. Biol. Chem. 281 2006 26424 26436
37. Z.-W. Zhang, Z.-M. Yang, Y.-C. Zheng, and Z.-D. Chen Transgelin induces apoptosis of human prostate LNCaP cells through its interaction with p53 Asian J. Andrology 12 2010 186 195
38. Z. Yang, Y.J. Chang, H. Miyamoto, and J. Ni et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth Mol. Endocrinol. 21 2007 343 358
39. P. Dong, X.W. He, J. Gu, and W.G. Wu et al. Vimentin significantly promoted gallbladder carcinoma metastasis Chin. Med. J. (Engl) 124 2011 4236 4244
40. W. Wang, K.X. Ai, Z. Yuan, and X.Y. Huang et al. Different expression of S100A8 in malignant and benign gallbladder diseases Dig. Dis. Sci. 58 2013 150 162
41. J.H. Kwon, J. Kim, J.Y. Park, and S.M. Hong et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma Clin. Cancer Res. 16 2010 5511 5521
42. W. Wang, H. Jiang, H. Zhu, and H. Zhang et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma Oncol. Lett. 5 2013 884 888
43. M. Gronborg, T.Z. Kristiansen, A. Iwahori, and R. Chang et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach Mol. Cell. Proteomics 5 2006 157 171